There may be new hope for many cancer patients, their caregivers and loved ones.
That’s because America’s research-based pharmaceutical companies are today developing nearly 400 new medicines to treat cancer, according to a survey of ongoing research conducted by the Pharmaceutical Research and Manufacturers of America (PhRMA).
Many of the medicines now in development represent potential breakthrough cancer treatments, while others involve possible new uses for existing medicines.
The medicines in development are all either in clinical trials or under review by the Food and Drug Administration. They include:
• 62 for lung cancer, the leading cause of cancer death in the United States;
• 49 for breast cancer, which is expected to strike more than 200,000 American women this year;
• 50 for prostate cancer, which is expected to kill more than 30,000 American men this year; and
• 35 for colorectal cancer, the third most common cancer in both men and women in the U.S.
Other potential medicines target kidney cancer, pancreatic cancer, brain cancer, skin cancer, ovarian cancer and...